Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31055084 | 0.96 | CRBN (0.53) | CRBNIKZF1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL31055102 | 0.90 | CRBN (0.52) | CRBNIKZF1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL31055282 | 0.87 | IKZF1 (0.55) | CRBNIKZF1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL31055154 | 0.87 | CRBN (0.56) | CRBNIKZF1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL31055270 | 0.86 | CRBN (0.52) | CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL31055244 | 0.86 | CRBN (0.43) | CRBNIKZF1CSNK1A1IKZF2DDB1 | |
| SCHEMBL31055195 | 0.86 | IKZF2 (0.48) | CRBNIKZF1CSNK1A1IKZF2IKZF3 | |
| SCHEMBL31055272 | 0.85 | IKZF1 (0.59) | CRBNIKZF1CSNK1A1IKZF2IKZF3 | |
| SCHEMBL31055334 | 0.85 | CRBN (0.50) | CRBNIKZF1CSNK1A1IKZF2GSPT1 | |
| SCHEMBL31055202 | 0.85 | CRBN (0.50) | CRBNIKZF1CSNK1A1IKZF2GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320193-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-16 | — | — | US | claimed |
| CN-118556047-A | Oxo-isoindolinyl substituted piperidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2024-08-27 | — | — | CN | claimed |
| US-20250320193-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-16 | — | — | US | disclosed |
| CN-118556047-A | Oxo-isoindolinyl substituted piperidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2024-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320193-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | CLN6, PSEN2, CRBN | CRBN 3/4885IKZF1 1829/4885CSNK1A1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.